HIGHLIGHTS
SUMMARY
The aim of this meta-analysis was to provide updated evidence on the safety and efficacy of rasagiline as adjunct therapy on motor and nonmotor symptoms, assessed by UPDRS and MDS-UPDRS, as well as healthrelated QOL such as PDQ-39, in levodopa-treated patients with PD experiencing motor fluctuations. The secondary outcomes were changed from baseline in UPDRS/MDS-UPDRS II + III, UPDRS/MDS-UPDRS II, and PDQ-39 summary index score. In this meta-analysis, significant improvements in wearing-off time, levodopa dosage, UPDRS/MDS-UPDRS II and III scores, and PDQ . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.